Printer Friendly

THE LIPOSOME COMPANY IS GRANTED PATENT COVERING COMPLEXES OF AMPHOTERICIN B AND CHOLESTEROL

 THE LIPOSOME COMPANY IS GRANTED PATENT COVERING
 COMPLEXES OF AMPHOTERICIN B AND CHOLESTEROL
 PRINCETON, N.J., Jan. 3 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO) announced today that it has been granted U.S. Patent No. 5,059,591 covering the use of lipids in non-liposomal formulations to buffer the toxicity of certain drugs while retaining their pharmacological activity. Among other things, the patent covers amphotericin B complexed with cholesterol or certain of its derivatives for the treatment of fungal infections.
 "Preparations containing amphotericin B and cholesterol for the treatment of fungal infections are specifically claimed in this patent," said Allen Bloom, J.D., Ph.D., vice president and general counsel, of The Liposome Company. "Anyone who makes, uses or sells a product containing amphotericin B and a cholesterol or sterol, or a water soluble derivative thereof, for use in treating fungal infections will violate this patent. It is our policy to enforce all of our patents vigorously against infringers."
 The Liposome Company's product, ABLC (amphotedoin B lipid complex), which has been licensed to Bristol-Myers Squibb, has been in advanced clinical trials for the treatment of systemic fungal infections.
 The largest company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, The Liposome Company selectively develops proprietary parenteral pharmaceuticals for the treatment and diagnosis of life-threatening illnesses. The Liposome Company's most advanced products treatment cancer and serious bacterial and fungal infections in immunocompromised patients, such as those with cancer and AIDS.
 -0- 1/3/92
 /CONTACT: Marc J. Ostro, vice chairman and chief science officer of the Liposome Company, 609-452-7060/
 (LIPO) CO: The Liposome Company ST: New Jersey IN: MTC SU: PDT


TS-PS -- NY002 -- 6380 01/03/92 08:43 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 3, 1992
Words:282
Previous Article:ANNTAYLOR REPORTS DECEMBER SALES
Next Article:CENTEL UNIT TO REDEEM FIRST MORTGAGE BONDS
Topics:


Related Articles
LIPOSOME ACQUIRES CLOT-BUSTER TECHNOLOGY FOR HEART ATTACKS; PATENT TO COVER LIPOSOME-ENCAPSULATED FIBRINOLYTIC AGENTS FOR ARTERY REOPENING
THE LIPOSOME COMPANY GAINS PATENT FOR LIPOSOMAL PROSTAGLANDIN; TLC C-53 BEING DEVELOPED FOR ARDS, SEPSIS/TRAUMA SYNDROME, AMI AND ANGIOPLASTY
VESTAR FILES COUNTERCLAIM VS. THE LIPOSOME COMPANY: ALLEGES THAT PATENT IS INVALID AND DENIES INFRINGEMENT
LIPOSOME TECHNOLOGY, INC. ANNOUNCES JUDGMENT
THE LIPOSOME COMPANY, INC. MAKES SUPPLEMENTAL FILING WITH U.S. FDA FOR ABELCET
The Liposome Company's ABELCET Approved in Greece For Treatment of Severe Systemic Fungal Infections
The Liposome Company Granted Marketing Approval For ABELCET In Finland
The Liposome Company Receives Notice Of Allowance From U.S. Patent And Trademark Office Of Additional Patent For ABELCET
The Liposome Company Granted Marketing Approval for ABELCET(R) in Canada
Eleventh United States patent issued for Esperion's peptide program.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters